PMC:7247521 / 993-1888 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"29","span":{"begin":155,"end":161},"obj":"Gene"},{"id":"30","span":{"begin":172,"end":176},"obj":"Gene"},{"id":"31","span":{"begin":263,"end":267},"obj":"Gene"},{"id":"32","span":{"begin":667,"end":676},"obj":"Gene"},{"id":"34","span":{"begin":784,"end":793},"obj":"Species"},{"id":"38","span":{"begin":423,"end":428},"obj":"Chemical"},{"id":"40","span":{"begin":49,"end":61},"obj":"Disease"},{"id":"41","span":{"begin":71,"end":92},"obj":"Disease"},{"id":"42","span":{"begin":94,"end":100},"obj":"Disease"},{"id":"43","span":{"begin":102,"end":139},"obj":"Disease"},{"id":"44","span":{"begin":249,"end":258},"obj":"Disease"},{"id":"45","span":{"begin":862,"end":870},"obj":"Disease"}],"attributes":[{"id":"A29","pred":"tao:has_database_id","subj":"29","obj":"Gene:406959"},{"id":"A30","pred":"tao:has_database_id","subj":"30","obj":"Gene:1022"},{"id":"A31","pred":"tao:has_database_id","subj":"31","obj":"Gene:59272"},{"id":"A34","pred":"tao:has_database_id","subj":"34","obj":"Tax:2697049"},{"id":"A40","pred":"tao:has_database_id","subj":"40","obj":"MESH:D003141"},{"id":"A41","pred":"tao:has_database_id","subj":"41","obj":"MESH:D007249"},{"id":"A42","pred":"tao:has_database_id","subj":"42","obj":"MESH:D001249"},{"id":"A43","pred":"tao:has_database_id","subj":"43","obj":"MESH:D029424"},{"id":"A44","pred":"tao:has_database_id","subj":"44","obj":"MESH:D011014"},{"id":"A45","pred":"tao:has_database_id","subj":"45","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"pathway, adipocytokine signaling pathway, etc.), TTD diseases (chronic inflammatory diseases, asthma, chronic obstructive pulmonary Disease, etc.), miRNA (MIR183), kinase (CDK7) and TF (LXR). QFPD contained 257 specific targets in addition to HCoV, pneumonia and ACE2 co-expression proteins. Then, network topology analysis of the five components-target-pathway-disease networks yielded 67 active ingredients. In addition, ADMET estimations showed that 20 compounds passed the stringent lead-like criteria and in silico drug-likeness test with high gastrointestinal absorption and the median lethal dose (LD50 \u003e 1600 mg/kg). Moreover, 4 specific ingredients (M3, S1, X2 and O2) and 5 common ingredients (MS1, MX16, SX1, WO1 and XO1) of QFPD presented good molecular docking score for 2019-nCov structure and non-structure proteins. Finally, drug perturbation of COVID-19 network robustness showe"}

{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T23","span":{"begin":122,"end":131},"obj":"UBERON:0002048"},{"id":"T24","span":{"begin":148,"end":153},"obj":"SO:0000276"},{"id":"T25","span":{"begin":172,"end":176},"obj":"PR:000005265"},{"id":"T26","span":{"begin":263,"end":267},"obj":"G_3;PG_10;PR:000003622"},{"id":"T27","span":{"begin":271,"end":281},"obj":"GO:0010467"},{"id":"T28","span":{"begin":456,"end":465},"obj":"CHEBI:36357;CHEBI:36357"},{"id":"T29","span":{"begin":520,"end":524},"obj":"CHEBI:23888;CHEBI:23888"},{"id":"T30","span":{"begin":549,"end":565},"obj":"UBERON:0001555"},{"id":"T31","span":{"begin":674,"end":676},"obj":"CHEBI:15379;CHEBI:15379"},{"id":"T32","span":{"begin":784,"end":793},"obj":"SP_7"},{"id":"T33","span":{"begin":841,"end":845},"obj":"CHEBI:23888;CHEBI:23888"},{"id":"T34","span":{"begin":862,"end":870},"obj":"SP_7"}],"text":"pathway, adipocytokine signaling pathway, etc.), TTD diseases (chronic inflammatory diseases, asthma, chronic obstructive pulmonary Disease, etc.), miRNA (MIR183), kinase (CDK7) and TF (LXR). QFPD contained 257 specific targets in addition to HCoV, pneumonia and ACE2 co-expression proteins. Then, network topology analysis of the five components-target-pathway-disease networks yielded 67 active ingredients. In addition, ADMET estimations showed that 20 compounds passed the stringent lead-like criteria and in silico drug-likeness test with high gastrointestinal absorption and the median lethal dose (LD50 \u003e 1600 mg/kg). Moreover, 4 specific ingredients (M3, S1, X2 and O2) and 5 common ingredients (MS1, MX16, SX1, WO1 and XO1) of QFPD presented good molecular docking score for 2019-nCov structure and non-structure proteins. Finally, drug perturbation of COVID-19 network robustness showe"}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T2","span":{"begin":282,"end":290},"obj":"Body_part"},{"id":"T3","span":{"begin":822,"end":830},"obj":"Body_part"}],"attributes":[{"id":"A2","pred":"fma_id","subj":"T2","obj":"http://purl.org/sig/ont/fma/fma67257"},{"id":"A3","pred":"fma_id","subj":"T3","obj":"http://purl.org/sig/ont/fma/fma67257"}],"text":"pathway, adipocytokine signaling pathway, etc.), TTD diseases (chronic inflammatory diseases, asthma, chronic obstructive pulmonary Disease, etc.), miRNA (MIR183), kinase (CDK7) and TF (LXR). QFPD contained 257 specific targets in addition to HCoV, pneumonia and ACE2 co-expression proteins. Then, network topology analysis of the five components-target-pathway-disease networks yielded 67 active ingredients. In addition, ADMET estimations showed that 20 compounds passed the stringent lead-like criteria and in silico drug-likeness test with high gastrointestinal absorption and the median lethal dose (LD50 \u003e 1600 mg/kg). Moreover, 4 specific ingredients (M3, S1, X2 and O2) and 5 common ingredients (MS1, MX16, SX1, WO1 and XO1) of QFPD presented good molecular docking score for 2019-nCov structure and non-structure proteins. Finally, drug perturbation of COVID-19 network robustness showe"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T6","span":{"begin":71,"end":92},"obj":"Disease"},{"id":"T7","span":{"begin":94,"end":100},"obj":"Disease"},{"id":"T8","span":{"begin":102,"end":139},"obj":"Disease"},{"id":"T9","span":{"begin":249,"end":258},"obj":"Disease"},{"id":"T10","span":{"begin":862,"end":870},"obj":"Disease"}],"attributes":[{"id":"A6","pred":"mondo_id","subj":"T6","obj":"http://purl.obolibrary.org/obo/MONDO_0021166"},{"id":"A7","pred":"mondo_id","subj":"T7","obj":"http://purl.obolibrary.org/obo/MONDO_0004979"},{"id":"A8","pred":"mondo_id","subj":"T8","obj":"http://purl.obolibrary.org/obo/MONDO_0005002"},{"id":"A9","pred":"mondo_id","subj":"T9","obj":"http://purl.obolibrary.org/obo/MONDO_0005249"},{"id":"A10","pred":"mondo_id","subj":"T10","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"pathway, adipocytokine signaling pathway, etc.), TTD diseases (chronic inflammatory diseases, asthma, chronic obstructive pulmonary Disease, etc.), miRNA (MIR183), kinase (CDK7) and TF (LXR). QFPD contained 257 specific targets in addition to HCoV, pneumonia and ACE2 co-expression proteins. Then, network topology analysis of the five components-target-pathway-disease networks yielded 67 active ingredients. In addition, ADMET estimations showed that 20 compounds passed the stringent lead-like criteria and in silico drug-likeness test with high gastrointestinal absorption and the median lethal dose (LD50 \u003e 1600 mg/kg). Moreover, 4 specific ingredients (M3, S1, X2 and O2) and 5 common ingredients (MS1, MX16, SX1, WO1 and XO1) of QFPD presented good molecular docking score for 2019-nCov structure and non-structure proteins. Finally, drug perturbation of COVID-19 network robustness showe"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T8","span":{"begin":23,"end":32},"obj":"http://purl.obolibrary.org/obo/SO_0000418"},{"id":"T9","span":{"begin":390,"end":396},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"},{"id":"T10","span":{"begin":534,"end":538},"obj":"http://purl.obolibrary.org/obo/UBERON_0000473"},{"id":"T11","span":{"begin":663,"end":665},"obj":"http://purl.obolibrary.org/obo/CLO_0050050"},{"id":"T12","span":{"begin":704,"end":707},"obj":"http://purl.obolibrary.org/obo/CLO_0007875"},{"id":"T13","span":{"begin":704,"end":707},"obj":"http://purl.obolibrary.org/obo/CLO_0052410"}],"text":"pathway, adipocytokine signaling pathway, etc.), TTD diseases (chronic inflammatory diseases, asthma, chronic obstructive pulmonary Disease, etc.), miRNA (MIR183), kinase (CDK7) and TF (LXR). QFPD contained 257 specific targets in addition to HCoV, pneumonia and ACE2 co-expression proteins. Then, network topology analysis of the five components-target-pathway-disease networks yielded 67 active ingredients. In addition, ADMET estimations showed that 20 compounds passed the stringent lead-like criteria and in silico drug-likeness test with high gastrointestinal absorption and the median lethal dose (LD50 \u003e 1600 mg/kg). Moreover, 4 specific ingredients (M3, S1, X2 and O2) and 5 common ingredients (MS1, MX16, SX1, WO1 and XO1) of QFPD presented good molecular docking score for 2019-nCov structure and non-structure proteins. Finally, drug perturbation of COVID-19 network robustness showe"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T4","span":{"begin":49,"end":52},"obj":"Chemical"},{"id":"T5","span":{"begin":182,"end":184},"obj":"Chemical"},{"id":"T6","span":{"begin":282,"end":290},"obj":"Chemical"},{"id":"T7","span":{"begin":520,"end":524},"obj":"Chemical"},{"id":"T8","span":{"begin":659,"end":661},"obj":"Chemical"},{"id":"T10","span":{"begin":674,"end":676},"obj":"Chemical"},{"id":"T11","span":{"begin":822,"end":830},"obj":"Chemical"},{"id":"T12","span":{"begin":841,"end":845},"obj":"Chemical"}],"attributes":[{"id":"A4","pred":"chebi_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/CHEBI_73659"},{"id":"A5","pred":"chebi_id","subj":"T5","obj":"http://purl.obolibrary.org/obo/CHEBI_74862"},{"id":"A6","pred":"chebi_id","subj":"T6","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"},{"id":"A7","pred":"chebi_id","subj":"T7","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A8","pred":"chebi_id","subj":"T8","obj":"http://purl.obolibrary.org/obo/CHEBI_51083"},{"id":"A9","pred":"chebi_id","subj":"T8","obj":"http://purl.obolibrary.org/obo/CHEBI_53453"},{"id":"A10","pred":"chebi_id","subj":"T10","obj":"http://purl.obolibrary.org/obo/CHEBI_15379"},{"id":"A11","pred":"chebi_id","subj":"T11","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"},{"id":"A12","pred":"chebi_id","subj":"T12","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"}],"text":"pathway, adipocytokine signaling pathway, etc.), TTD diseases (chronic inflammatory diseases, asthma, chronic obstructive pulmonary Disease, etc.), miRNA (MIR183), kinase (CDK7) and TF (LXR). QFPD contained 257 specific targets in addition to HCoV, pneumonia and ACE2 co-expression proteins. Then, network topology analysis of the five components-target-pathway-disease networks yielded 67 active ingredients. In addition, ADMET estimations showed that 20 compounds passed the stringent lead-like criteria and in silico drug-likeness test with high gastrointestinal absorption and the median lethal dose (LD50 \u003e 1600 mg/kg). Moreover, 4 specific ingredients (M3, S1, X2 and O2) and 5 common ingredients (MS1, MX16, SX1, WO1 and XO1) of QFPD presented good molecular docking score for 2019-nCov structure and non-structure proteins. Finally, drug perturbation of COVID-19 network robustness showe"}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T1","span":{"begin":94,"end":100},"obj":"Phenotype"},{"id":"T2","span":{"begin":102,"end":139},"obj":"Phenotype"},{"id":"T3","span":{"begin":249,"end":258},"obj":"Phenotype"}],"attributes":[{"id":"A1","pred":"hp_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/HP_0002099"},{"id":"A2","pred":"hp_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/HP_0006510"},{"id":"A3","pred":"hp_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/HP_0002090"}],"text":"pathway, adipocytokine signaling pathway, etc.), TTD diseases (chronic inflammatory diseases, asthma, chronic obstructive pulmonary Disease, etc.), miRNA (MIR183), kinase (CDK7) and TF (LXR). QFPD contained 257 specific targets in addition to HCoV, pneumonia and ACE2 co-expression proteins. Then, network topology analysis of the five components-target-pathway-disease networks yielded 67 active ingredients. In addition, ADMET estimations showed that 20 compounds passed the stringent lead-like criteria and in silico drug-likeness test with high gastrointestinal absorption and the median lethal dose (LD50 \u003e 1600 mg/kg). Moreover, 4 specific ingredients (M3, S1, X2 and O2) and 5 common ingredients (MS1, MX16, SX1, WO1 and XO1) of QFPD presented good molecular docking score for 2019-nCov structure and non-structure proteins. Finally, drug perturbation of COVID-19 network robustness showe"}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T10","span":{"begin":9,"end":40},"obj":"http://purl.obolibrary.org/obo/GO_0033211"},{"id":"T11","span":{"begin":9,"end":40},"obj":"http://purl.obolibrary.org/obo/GO_0033210"},{"id":"T12","span":{"begin":9,"end":40},"obj":"http://purl.obolibrary.org/obo/GO_0033209"},{"id":"T13","span":{"begin":23,"end":40},"obj":"http://purl.obolibrary.org/obo/GO_0007165"},{"id":"T14","span":{"begin":23,"end":32},"obj":"http://purl.obolibrary.org/obo/GO_0023052"},{"id":"T15","span":{"begin":182,"end":184},"obj":"http://purl.obolibrary.org/obo/GO_0000981"}],"text":"pathway, adipocytokine signaling pathway, etc.), TTD diseases (chronic inflammatory diseases, asthma, chronic obstructive pulmonary Disease, etc.), miRNA (MIR183), kinase (CDK7) and TF (LXR). QFPD contained 257 specific targets in addition to HCoV, pneumonia and ACE2 co-expression proteins. Then, network topology analysis of the five components-target-pathway-disease networks yielded 67 active ingredients. In addition, ADMET estimations showed that 20 compounds passed the stringent lead-like criteria and in silico drug-likeness test with high gastrointestinal absorption and the median lethal dose (LD50 \u003e 1600 mg/kg). Moreover, 4 specific ingredients (M3, S1, X2 and O2) and 5 common ingredients (MS1, MX16, SX1, WO1 and XO1) of QFPD presented good molecular docking score for 2019-nCov structure and non-structure proteins. Finally, drug perturbation of COVID-19 network robustness showe"}

{"project":"LitCovid-sentences","denotations":[{"id":"T13","span":{"begin":192,"end":291},"obj":"Sentence"},{"id":"T14","span":{"begin":292,"end":409},"obj":"Sentence"},{"id":"T15","span":{"begin":410,"end":624},"obj":"Sentence"},{"id":"T16","span":{"begin":625,"end":831},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"pathway, adipocytokine signaling pathway, etc.), TTD diseases (chronic inflammatory diseases, asthma, chronic obstructive pulmonary Disease, etc.), miRNA (MIR183), kinase (CDK7) and TF (LXR). QFPD contained 257 specific targets in addition to HCoV, pneumonia and ACE2 co-expression proteins. Then, network topology analysis of the five components-target-pathway-disease networks yielded 67 active ingredients. In addition, ADMET estimations showed that 20 compounds passed the stringent lead-like criteria and in silico drug-likeness test with high gastrointestinal absorption and the median lethal dose (LD50 \u003e 1600 mg/kg). Moreover, 4 specific ingredients (M3, S1, X2 and O2) and 5 common ingredients (MS1, MX16, SX1, WO1 and XO1) of QFPD presented good molecular docking score for 2019-nCov structure and non-structure proteins. Finally, drug perturbation of COVID-19 network robustness showe"}

{"project":"LitCovid-PD-GlycoEpitope","denotations":[{"id":"T1","span":{"begin":720,"end":723},"obj":"GlycoEpitope"}],"attributes":[{"id":"A1","pred":"glyco_epitope_db_id","subj":"T1","obj":"http://www.glycoepitope.jp/epitopes/AN0690"}],"text":"pathway, adipocytokine signaling pathway, etc.), TTD diseases (chronic inflammatory diseases, asthma, chronic obstructive pulmonary Disease, etc.), miRNA (MIR183), kinase (CDK7) and TF (LXR). QFPD contained 257 specific targets in addition to HCoV, pneumonia and ACE2 co-expression proteins. Then, network topology analysis of the five components-target-pathway-disease networks yielded 67 active ingredients. In addition, ADMET estimations showed that 20 compounds passed the stringent lead-like criteria and in silico drug-likeness test with high gastrointestinal absorption and the median lethal dose (LD50 \u003e 1600 mg/kg). Moreover, 4 specific ingredients (M3, S1, X2 and O2) and 5 common ingredients (MS1, MX16, SX1, WO1 and XO1) of QFPD presented good molecular docking score for 2019-nCov structure and non-structure proteins. Finally, drug perturbation of COVID-19 network robustness showe"}